Search

Displaying results 6881 - 6890 of 10000 in total
  1. Drug

    Duvortuxizumab

    go.drugbank.com/drugs/DB15211
    Investigational

    Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).

  2. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    ≥ 1) Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck). … Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

  3. Drug

    Fluorfenidine F-18

    go.drugbank.com/drugs/DB19557
    Experimental

    The usage of the INN stem '-nidine' in the name indicates that Fluorfenidine F-18 is a a2 adrenoreceptor agonist. Fluorfenidine F-18 has a monoisotopic molecular weight of 382.07 Da.

  4. Drug

    Dalzanemdor

    go.drugbank.com/drugs/DB21549
    Investigational

    Dalzanemdor has a monoisotopic molecular weight of 456.32 Da. … Dalzanemdor is under investigation in clinical trial NCT05655520 (A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease).

  5. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

  6. Drug

    Fedovapagon

    go.drugbank.com/drugs/DB11734
    Investigational

    Fedovapagon has been used in trials studying the treatment of Nocturia.

  7. Drug

    Brivanib alaninate

    go.drugbank.com/drugs/DB11865
    Investigational

    Brivanib alaninate has been investigated for the treatment of Colorectal Cancer.

  8. Drug

    Asiatic acid

    go.drugbank.com/drugs/DB14054
    Investigational

    From Centella asiatica and other plants; shows a variety of bioactivities.

  9. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  10. Drug

    Apc001

    go.drugbank.com/drugs/DB17819
    Experimental

    Apc001 is an aptamer developed for the treatment of osteogenesis imperfecta.